Nanexa: Q2’21 Report - ABG

Important events during and after the quarter
Important events during the quarter included the start of the first-in-human Ph I trial of NEX-18, where results have been expected during Q3’21. Due to a greater than expected impact from the ongoing COVID-19 pandemic, management indicate in the Q2 report today that enrolment has been slower than anticipated and that it has decided to add another study site in Sweden in addition to the previously communicated sites in Stockholm and Uppsala. With the future impact of the pandemic and the expected positive impact from study site additions difficult to predict, no precise new timeline was communicated at this time. During Q2 Nanexa also received a second investment from Applied Ventures of SEK 4.3m. There were also significant developments related to Nanexa’s IP position. A patent in China covering the manufacturing method, products that come out of it, and the use of PharmaShell®-coated drugs was granted in Q2, followed by South Korea in Q3, adding to the list of already granted countries that includes the US and Japan, with filings also having been made in the European Patent Office (intention to grant communicated), Canada, and India. Nanexa also brought suit agents a Colorado-based company utilizing an ALD tech platform to engineer thermostable, single-shot vaccines (see our note from 31.5.2021), with this process progressing as expected but with no other updated in the report.